Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Apolipoprotein A-IV (APOA4)
- Target
- APOA4
- Molecular classification
- Apolipoprotein, Plasma protein, Component of lipoproteins (primarily HDL and chylomicrons), Other (exchangeable apolipoprotein)
01
Overview
Apolipoprotein A-IV (APOA4) is a plasma glycoprotein primarily synthesized in the intestine and secreted on the surface of newly formed chylomicrons, as well as incorporated into high-density lipoproteins (HDL). APOA4 acts as an important mediator of lipid transport and metabolism, facilitating cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1), activating cholesterol esterification through LCAT, and exerting antioxidant effects by protecting low-density lipoprotein (LDL) from oxidation. It also plays roles in the regulation of appetite, satiety, and has anti-atherogenic and anti-inflammatory properties. Genetic polymorphisms in APOA4 may influence lipid metabolism and cardiovascular risk, and raised APOA4 levels have been associated with a reduction in atherosclerosis in animal models.
- Other names
- Apolipoprotein A4Apo-AIVApoA-IVapolipoprotein A-IVADTKD6apoA4apoAIV
02
Mechanism of action
Drugs or interventions (experimental) may aim to elevate or mimic APOA4 to promote reverse cholesterol transport or inhibit lipid oxidation (mechanism: enhancement of cholesterol efflux, LCAT activation, and antioxidant effects)
03
Biological functions
Lipid transportLipid absorption and chylomicron assemblyRegulation of appetite and satietyActivation of lecithin-cholesterol acyltransferase (LCAT)Promotion of cholesterol efflux via ABCA1Reverse cholesterol transportAntioxidant activity (protection against LDL oxidation)Modulation of inflammation
04
Disease associations
Cardiovascular disease (atherosclerosis, protective role)Obesity/metabolic syndrome (appetite regulation, fat absorption)Neurodegenerative disease (linked with amyloid-β clearance)Inflammation
05
Safety considerations
No major safety concerns or toxicity reported (APOA4 deficiency has not been found in humans, suggesting redundancy or compensation)Therapeutic challenges include difficulty in targeting plasma proteins and delivering protein/peptide therapies effectively
06
Interacting drugs
No direct apolipoprotein A-IV–targeting drugs are approved; no drugs are explicitly listed in current sources as direct interactors
07
Biomarkers
APOA4 plasma levels are biomarkers for lipid absorption/metabolism, cardiovascular risk, and may serve as indicators of HDL function and metabolic status
Beyond the preview
Go deeper on Apolipoprotein A-IV (APOA4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apolipoprotein A-IV (APOA4).